

Supplemental Material to:

**Wei Ma, Jing Ma, Jie Xu, Chong Qiao, Adam Branscum,
Andres Cardenas, Andre T. Baron, Peter Schwartz,
Nita J. Maihle and Yingqun Huang**

**Lin28 regulates BMP4 and functions with Oct4
to affect ovarian tumor microenvironment**

Cell Cycle 2012; 12(1)

<http://dx.doi.org/10.4161/cc.23028>

<http://www.landesbioscience.com/journals/cc/article/23028>




Table S1. Characteristics of Yale Ovarian Cancer Cohort (N=343)

		Kruskal-Wallis or Wilcoxon-Rank sum test	
Variable	Patient number (N)	Lin28 Expression: mean (SD)	Oct4 Expression: mean (SD)
Race	331	P-value (0.423)	P-value (0.238)
White	308	425.00 (586.76)	66.54 (91.57)
Black	8	477.04 (802.21)	26.55 (38.30)
Other	15	562.43 (526.66)	62.87 (51.71)
Category of Specimen	343	P-value (0.469)	P-value (0.194)
Fallopian Tube	16	467.86 (658.19)	102.77 (101.06)
EOC	285	450.09 (605.75)	66.26 (93.59)
LMP	5	234.25 (523.80)	44.40 (60.92)
Non-Gyn	15	322.20 (430.82)	36.23 (44.67)
Other Gyn	22	298.49 (316.05)	64.06 (52.25)
Bilateral Involvement (BOI)	326	P-value (0.743)	P-value (0.298)
Yes	169	415.84 (560.72)	73.36 (109.27)
No	157	452.43 (611.09)	59.08 (67.17)
Histology	320	P-value (0.342)	P-value (0.845)
Serous	142	395.90 (446.59)	67.42 (104.45)
Mucinous	16	303.76 (446.16)	52.88 (56.75)
Endometrioid	71	459.15 (694.62)	63.19 (61.43)
Clear Cell	28	693.67 (931.00)	55.10 (61.74)
Transitional	5	343.23 (577.74)	21.55 (48.20)
Mixed	39	488.21 (695.63)	77.34 (109.67)
Other	19	367.70 (447.43)	68.16 (99.80)
Stage	337	P-value (0.406)	P-value (0.811)
I	62	479.27 (598.56)	67.55 (75.06)
II	40	532.48 (833.26)	79.02 (173.88)
III	147	449.64 (584.61)	62.82 (63.48)
IV	53	359.73 (462.25)	72.96 (102.45)
MET	35	291.55 (362.16)	50.38 (50.29)
Grade	336	P-value (0.785)	P-value (0.151)
1	32	375.86 (488.45)	52.46 (63.86)
2	79	448.61 (649.96)	49.40 (47.66)
3	225	437.78 (582.53)	70.19 (79.96)
Chemo Regimen	255	P-value (0.126)	P-value (0.825)
No treatment after surgery	40	501.79 (637.48)	57.29 (56.77)
Adriamycin + Platinum or CAP	54	239.65 (280.27)	55.35 (66.73)
Platinum/Taxol	43	567.08 (798.46)	68.35 (67.48)
Cytosin/Platinum	64	437.99 (474.69)	69.85 (96.61)
Other chemo regimen	34	332.44 (275.31)	69.58 (78.01)
XRT as first treatment	20	312.00 (275.48)	66.69 (55.59)
Age	343	Spearman Correlation (P-value)	
Mean, Median, SD,[Range]	60.78,62,13.27, [18-91]	0.0192 (0.729)	-0.0325 (0.548)
Lin28	343		
Mean, Median, SD,[Range]	668.16,504.98,610.68, [0-4889.49]	-----	0.432 (<0.001)
Oct4	343		
Mean, Median, SD,[Range]	110.22,87.88,93.15, [0-1063.58]	0.432 (<0.001)	-----

Covariates	Univariate Model		Multivariate Model	
	PFS	OS	PFS	OS
Age	<0.001	<0.001	<0.001	<0.001
Stage	<0.001	<0.001	<0.001	
Grade	<0.001	<0.001		
Histology	<0.001	<0.001		
BOI	<0.001	<0.001		
Category	0.091	0.158		
Lin28	0.866	0.868	0.149	0.103
Oct4	0.529	0.409	0.081	0.137
Lin28/Oct4			0.038	0.036

Variables	Progression Free Survival	Overall Survival
	OR (95% CI)	HR (95% CI)
High Lin28 / High Oct4	3.027 (1.004, 9.127)	2.058 (1.000, 4.239)
High Lin28 / No Oct4	1.129 (0.550, 2.315)	0.752 (0.348, 1.626)
No Lin28 / High Oct4 (referent)	1.000	1.000
High Lin28 / Medium Oct4	1.799 (0.856, 3.779)	1.338 (0.805, 2.225)
Medium Lin28 / High Oct4	1.578 (1.001, 2.486)	1.346 (1.000, 1.813)
Medium Lin28 / Medium Oct4	1.557 (0.940, 2.580)	1.283 (0.897, 1.836)
Medium Lin28 / No Oct4	1.539 (0.817, 2.899)	1.230 (0.753, 2.008)
No Lin28 / Medium Oct4	1.408 (0.958, 2.069)	1.246 (0.932, 1.667)
No Lin28 / No Oct4	1.913 (0.922, 3.969)	1.518 (0.876, 2.629)